Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242164 · ClinicalTrials.gov registry record · Phase 2
Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00242164 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 25 participants.
The verdict
NCT00242164, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study is being performed to better understand dialysis techniques which keep heart functions stable during dialysis. People on dialysis have a high risk for heart disease and strokes. More information about dialysis techniques that keep hearts stable may help prevent the high risk of cardiovascular disease and death and help to reduce discomfort during dialysis. This study will look at the way that the magnesium in dialysate affects heart function during dialysis. High or low levels of magnesium may change the way hearts beat. The question asked is if lowering the amount of magnesium in dialysate will affect the amount of magnesium in blood or change the heart beat.
Interventions
- DRUG Dialysate Magnesium (Concentration)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00242164
The ClinicalTrials.gov registry entry for NCT00242164 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dialysate Magnesium (Concentration) is the first listed.
NCT00242164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00242164 about?
NCT00242164 is a clinical study titled "Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis". The study is being performed to better understand dialysis techniques which keep heart functions stable during dialysis. People on dialysis have a high risk for heart disease and strokes. More information about dialysis techniques that keep hearts stable may help prevent the high risk of cardiovascu...
What is the current status of trial NCT00242164?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2005-11. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00242164?
The interventions under investigation include: Dialysate Magnesium (Concentration) (DRUG).
Who is sponsoring clinical trial NCT00242164?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.